COBENFY Drug Patent Profile
✉ Email this page to a colleague
When do Cobenfy patents expire, and when can generic versions of Cobenfy launch?
Cobenfy is a drug marketed by Bristol-myers and is included in one NDA.
The generic ingredient in COBENFY is trospium chloride; xanomeline tartrate. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trospium chloride; xanomeline tartrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COBENFY?
- What are the global sales for COBENFY?
- What is Average Wholesale Price for COBENFY?
Summary for COBENFY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 1,327 |
| What excipients (inactive ingredients) are in COBENFY? | COBENFY excipients list |
| DailyMed Link: | COBENFY at DailyMed |
US Patents and Regulatory Information for COBENFY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-001 | Sep 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-003 | Sep 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
